Special Issue Article
Advances in Radioembolization - Embolics and IsotopesJoshua Burrill1, Urs Hafeli2 and David M Liu3,4*
- *Corresponding Author:
- David Liu
Department of Radiology, Vancouver General Hospital
University of British, 855 W 12th Ave, JP Pavilion G873
Vancouver, British Columbia, Canada, V5Z 1M9
E-mail: [email protected]
Received date: April 26, 2011; Accepted date: May 26, 2011; Published date: June 15, 2011
Citation: Burrill J, Hafeli U, Liu DM (2011) Advances in Radioembolization - Embolics and Isotopes. J Nucl Med Radiat Ther 2:107. doi:10.4172/2155-9619.1000107
Copyright: © 2011 Burrill J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Selective internal radiation therapy (SIRT), otherwise known as radio embolization is now becoming a common procedure performed for those patients with primary hepatic neoplasia [such as hepatocellular carcinoma], and liver dominant metastatic disease [such as in near endocrine disease, and colorectal carcinoma]. The current technology platforms incorporate the use of yttrium 90, a pure beta emitter loaded on either a resin microsphere, or ceramic microsphere. Although clinical outcomes have been encouraging with both technology platforms, second-generation radioembolic devices [utilizing either new processes of microsphere synthesis, or different radioactive isotopes] are currently under development, or clinical study. The purpose of this manuscript is to provide the reader with some perspectives regarding the next generation of radioembolic devices, and discussing the advantages and disadvantages of both current, and future platforms.